Search Results 1341-1350 of 16393 for alt

1. A Safety Study of SGN-LIV1A in Breast Cancer Patients - Mayo Clinic

   alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤.5x ULN or ≤x ULN if liver metastases present . Females of childbearing potential ...

2. A Study To Assess The Safety, Tolerability, And Pharmacokinetics Of ABSK-011 In Patients With Advanced Solid Tumor - Mayo Clinic

   Aspartate transaminase (AST) and alanine transaminase (ALT), ≤3×ULN (for patient with liver metastasis in escalation part or patient in expansion part: AST and ...

3. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

   Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 × ULN for patients with known hepatic metastases). 11. Adequate renal ...

4. Durvalumab and Grid Therapy for the Treatment of Non-small Cell Lung Cancer in Patients Who Progressed During or After Treatment With the PACIFIC Regimen - Mayo Clinic

   Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement);; Creatinine OR glomerular ...

5. Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Relapsed/Refractory Large B-cell Lymphoma - Mayo Clinic

   Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 upper limit of normal (ULN);; Total bilirubin ≤ 1.5 mg/dL, except in subjects ...

6. A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies - Mayo Clinic

   AST/ALT ≤ 2 x ULN. If documented liver metastases, then ≤ 5X ULN;; Bilirubin: For monotherapy and pembrolizumab combination therapy cohorts: ≤ 2 x ULN; or ...

7. A Study to Evaluate Chemoradiotherapy with or without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer - Mayo Clinic

   Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x IULN (within 28 days prior to randomization). Patients must not have clinically ...

8. Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment - Mayo Clinic

   ... (ALT) serum glutamic-pyruvic transaminase (SGPT) ≤ 3 x institutional ULN. - Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m^2. - Human immunodeficiency ...

9. Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia - Mayo Clinic

   Serum aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤ 3.0 x upper limit of normal (ULN);; Total bilirubin ≤ 1.5 x ULN;; Estimated ...

10. A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis - Mayo Clinic

    * Alanine aminotransferase (ALT) ≥ 2 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≥ 2 × ULN, alkaline phosphatase and/or bilirubin ...